Management of allergic rhinitis with leukotriene receptor antagonists versus selective H1-antihistamines: a meta-analysis of current evidence

Yan Feng1,2, Ya‑Ping Meng1, Ying‑Ying Dong3, Chang‑Yu Qiu4 and Lei Cheng4,5*

Abstract

Background: Inconsistencies remain regarding the effectiveness and safety of leukotriene receptor antagonists (LTRAs) and selective H1-antihistamines (SAHs) for allergic rhinitis (AR). A meta-analysis of randomized controlled trials (RCTs) was conducted to compare the medications.

Methods: Relevant head-to-head comparative RCTs were retrieved by searching the PubMed, Embase, and Cochrane’s Library databases from inception to April 20, 2020. A random-effects model was applied to pool the results. Subgroup analyses were performed for seasonal and perennial AR.

Results: Fourteen RCTs comprising 4458 patients were included. LTRAs were inferior to SAHs in terms of the daytime nasal symptoms score (mean difference [MD]: 0.05, 95% confidence interval [CI] 0.02 to 0.08, \( p = 0.003 \), \( I^2 = 89\% \)) and daytime eye symptoms score (MD: 0.05, 95% CI 0.01 to 0.08, \( p = 0.009 \), \( I^2 = 89\% \)), but were superior in terms of the nighttime symptoms score (MD: −0.04, 95% CI −0.06 to −0.02, \( p < 0.001 \), \( I^2 = 85\% \)). The effects of the two treatments on the composite symptom score (MD: 0.02, 95% CI −0.02 to 0.05, \( p = 0.30 \), \( I^2 = 91\% \)) and rhinoconjunctivitis quality-of-life questionnaire (RQLQ) (MD: 0.01, 95% CI −0.05 to 0.07, \( p = 0.71 \), \( I^2 = 99\% \)) were similar. Incidences of adverse events were comparable (odds ratio [OR]: 0.97, 95% CI 0.75 to 1.25, \( p = 0.98 \), \( I^2 = 0\% \)). These results were mainly obtained from studies on seasonal AR. No significant publication bias was detected.

Conclusions: Although both treatments are safe and effective in improving the quality of life (QoL) in AR patients, LTRAs are more effective in improving nighttime symptoms but less effective in improving daytime nasal symptoms compared to SAHs.

Keywords: Allergic rhinitis, Leukotriene receptor antagonists, H1-antihistamines, Randomized controlled trials, Meta-analysis

Background

Allergic rhinitis (AR) is a common allergic disease caused by immunoglobulin E (IgE)-associated inflammation of the nasal membranes as a result of exposure to allergens [1, 2]. AR can be categorized as seasonal or perennial according to the persistence of the symptoms. Patients with AR are affected by nasal and eye symptoms, which interrupt their daily lives...
and sleep schedule, leading to impaired QoL [3]. The primary treatments for AR are allergen avoidance, pharmacotherapy, and immunotherapy [4, 5]. Among the oral medications available to relieve the symptoms of AR, leukotriene receptor antagonists (LTRAs) and selective H1-antihistamines (SAHs) are commonly prescribed [6]. By blocking cysteinyl leukotriene-activated inflammation in the nasal lavage fluids and airways, LTRAs effectively attenuate nasal obstruction and rhinorrhea [7]. SAHs selectively inhibit histamine 1 receptor (H1R)-mediated vasopermeability and vasodilatation and are widely utilized for relieving rhinorrhea and congestion in AR [8]. However, previous randomized controlled trials (RCTs) comparing the efficacy and safety of LTRAs and SAHs for patients with AR yielded inconsistent results [9–22]. Consequently, the recommendations for LTRA and SAH use for AR patients vary in different international guidelines [23]. The 2015 US Clinical Practice Guidelines for Allergic Rhinitis recommend oral second-generation/less sedating antihistamines for patients with AR who have primary complaints of sneezing and itching, but do not recommend LTRAs as the primary therapy for patients with AR [24]. In contrast, the 2017 Japanese Guidelines for Allergic Rhinitis suggest that LTRAs may be comparable to SAHs for sneezing and rhinorrhea in patients with moderate or mild nasal blockage [25]. The recent 2018 Chinese Society of Allergy Guidelines for Diagnosis and Treatment of Allergic Rhinitis suggest that LTRAs and SAHs may have similar efficacy, but that LTRAs may be better suited for night-time symptoms [26]. In view of the discrepancies regarding the role of LTRAs and SAHs in the treatment of AR, we aimed to perform a meta-analysis of head-to-head RCTs to compare the effects of the two medications on the symptoms, QoL, and adverse events (AEs) in patients with AR.

**Methods**

The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement [27] and the Cochrane Handbook guidelines [28] were followed during the design and implementation of the study.

**Search strategy**

PubMed, Embase, and the Cochrane Library (Cochrane Center Register of Controlled Trials) databases were systematically searched for relevant studies using the following combined strategy: (1) “leukotriene receptor antagonist” OR “LTRA” OR “montelukast” OR “zafirlukast” OR “pranlukast”; (2) “selective H1-antihistamine” OR “SAH” OR “cetirizine” OR “ebastine” OR “loratadine” OR “desloratadine” OR “acrivastine” OR “fexofenadine” OR “levocetirizine” OR “rupatadine”; (3) “allergic rhinitis”; and (4) “random” OR “randomized” OR “randomised” OR ”randomly”. Only clinical studies published in English or Chinese were considered. The reference lists for related reviews and original articles were also searched to complement the results. The latest database search was conducted on April 20, 2020.

**Study selection**

The inclusion criteria were: (1) peer-reviewed articles in English or Chinese; (2) designed as RCTs; (3) included patients with AR who were randomly allocated to receive LTRAs or SAHs with or without concomitant treatments; (4) with a treatment duration of at least 1 week; and (5) at least one of the following outcomes: daytime nasal symptoms score (DNSS), nighttime symptoms score (NSS), daytime eye symptoms score (DESS), composite symptoms score (CSS), RQLQ, and incidence of AEs. No restrictions were applied for the age of the patients or the blindness of the RCTs during the process of study inclusion. The DNSS includes four nasal symptoms (stuffy, runny, and itchy nose, and sneezing) and each symptom domain is scored from 0 to 3, with the highest score indicating the most serious symptoms. The NSS is calculated as the sum of the scores (0–12) [29]. Similarly, the DESS includes four eye symptoms (teary, itchy, red, and puffy eyes) with a score of 0–3 for each domain and is calculated as the sum of the scores (0–12, 12 indicating the most serious symptoms) [29]. The CSS evaluates nighttime symptoms based on three factors (nasal congestion on awakening, difficulty going to sleep, nighttime awakenings) with a score of 0–3 for each domain and is calculated as the sum of the scores (0–9, 9 indicating the most serious symptoms) [29–31]. The CSS is defined as a post hoc composite score that captures the treatment effect over 24 h (mean of DNSS and NSS) [29–31]. The RQLQ assesses the QoL in AR patients via seven domains (sleep, non-nose and non-eye symptoms, practical problems, nasal symptoms, eye symptoms, activities, and emotions) via a total of 28 questions. The ratings for each of the questions range from 0–6 points and a sum of 168 points indicates the worst QoL [32]. The definitions of AEs were in accordance with the original articles. Reviews, preclinical studies, observational studies, and repeated reports were excluded.

**Data extraction and quality assessment**

The study search, data extraction, and quality evaluation were performed independently by two of the authors and disagreements were resolved by consensus between them. We extracted data regarding the study information (first author, publication year, and study country), study design (blind or open-label, crossover or parallel design),
Statistical analysis
The effects of LTRAs and SAHs on continuous outcomes, including DNSS, NSS, CSS, DESS, and RQLQ were summarized as differences in the changes in each outcome from the baseline between the groups. MD was used as the measure of the effect on the continuous outcome and the CIs were extracted. For categorized outcomes such as the incidence of AEs, OR and corresponding CIs were used. We used the Cochrane’s Q test to assess heterogeneity, and significant heterogeneity was suggested if $p < 0.10$[33]. The $I^2$ statistic was also calculated, and an $I^2 > 50\%$ reflected significant heterogeneity. Pooled analyses were calculated using a random-effects model because this method incorporates the influence of potential heterogeneity and yields a more generalized result[28]. Sensitive analyses by excluding one dataset at a time were used to examine the stability of the findings. Subgroup analysis was also performed to evaluate the outcomes in patients with seasonal or perennial AR. Publication bias was evaluated by visual inspection of the funnel plots provided and by using Egger’s regression asymmetry test[34]. $p$ values $< 0.05$ were considered statistically significant. RevMan (Version 5.1; Cochrane, Oxford, UK) and Stata software (Version 12.0; Stata, College Station, TX) were applied for statistical analyses.

Results
Search results
In summary, 322 articles were obtained through the database search after excluding duplicates. Among them, 296 articles were subsequently excluded primarily based on the titles and abstracts because the studies were not relevant. Among the 26 potentially relevant articles, 12 were further excluded after a full-text review due to the reasons shown in Fig. 1. Finally, 14 RCTs comprising 4458 patients with child and adult AR were included[9–22].

Study characteristics
Table 1 shows the characteristics of the included studies. Overall, 14 RCTs[9–22] involving 4458 AR patients were included. One article included two RCTs[20], and another study[17] included two comparisons (montelukast 10 mg/d versus levocetirizine 5 mg/d, and montelukast 10 mg/d versus desloratadine 5 mg/d). These comparisons were included as independent datasets, resulting in a total of 16 datasets included in the meta-analysis. These studies were published between the years 2000 and 2017 and included AR patients from the United States, United Kingdom, Italy, Poland, and China. Eight of the studies included patients with seasonal AR[9–14, 20, 21], while six included perennial AR patients only[15–19, 22]. One study focused on pediatric patients (aged < 18 years)[15], two included only adult patients (aged ≥ 18 years)[16, 17], and the rest included both. For LTRA treatment, montelukast 10 mg/d was used in all but two studies in which montelukast 5 mg/d[15] and zafirlukast 40 mg/d[18] were used, respectively. For the SAHs, loratadine, fexofenadine, or desloratadine were used. Most of the included studies did not involve concomitant therapies for AR, although fluticasone propionate aqueous nasal spray was used in one study[14] and nasal mometasone was used for both groups in two studies[21, 22]. The treatment duration varied from 1 to 12 weeks.

Data quality
Table 2 shows the details of the study quality evaluation. Most of the included RCTs were randomized and double-blind except for three studies, which were randomized but open-label[18, 21, 22]. The methods used for random sequence generation were reported in eight studies and none of the included studies reported the details of allocation concealment. The overall quality score ranged between 2 and 6.

Meta-analysis results
Pooled results with 16 datasets from 14 RCTs showed that treatment with LTRAs was inferior to SAH treatment in terms of the DNSS (MD: 0.05, 95% CI 0.02 to 0.08, $p = 0.003$; Fig. 2A) with significant heterogeneity ($I^2 = 89\%$). Sensitivity analysis by excluding one dataset at a time showed similar results. Subgroup analyses also showed similar results for seasonal AR patients (MD: 0.06, 95% CI 0.03 to 0.09, $p < 0.001$) but not for perennial AR patients (MD: 0.02, CI 0.00 to 0.08, $p = 0.58$). However, the between-subgroup difference was not statistically significant ($p = 0.27$; Fig. 2A).

Meta-analysis of five studies[9–13] with seasonal AR patients showed that LTRAs were superior to SAHs in terms of the NSS (MD: −0.04, 95% CI −0.06 to −0.02, $p < 0.001$, $I^2 = 85\%$; Fig. 2B). Sensitivity analysis by excluding one dataset at a time showed similar results.
Meta-analysis of seven datasets from six studies [9–13, 20] with seasonal AR patients showed similar CSS between the two treatments (MD: 0.02, 95% CI −0.02 to 0.05, \(p=0.30\), \(I^2=91\%\); Fig. 2C). Sensitivity analysis by excluding one dataset at a time also showed similar results.

Pooled results with seven datasets from six RCTs [9–13, 17] showed that treatment with LTRA was inferior to SAH in terms of the DESS (MD: 0.05, 95% CI 0.01 to 0.08, \(p=0.009\), \(I^2=89\%\); Fig. 2D). Sensitivity analysis by excluding one dataset at a time showed similar results. Subgroup analyses showed similar results for seasonal AR patients (MD: 0.04, 95% CI 0.01 to 0.08, \(p=0.02\)) but not for perennial AR patients (MD: 0.07, CI −0.12 to 0.26, \(p=0.46\)). However, the between-subgroup difference was not statistically significant (\(p=0.77\); Fig. 2D).

Meta-analysis of seven studies [9–13, 19, 21] showed that RQLQ was not significantly different between the two groups (MD: 0.01, 95% CI −0.05 to 0.07, \(p=0.71\), \(I^2=99\%\); Fig. 3A). Sensitivity analysis by excluding one dataset at a time showed similar results. Subgroup analysis showed consistent results for seasonal AR
## Table 1 Characteristics of the included studies

| Author (year) | Country | Design | Patients | Patient number | Mean age (year) | Male (%) | With asthma (%) | LTRAs | SAHs | Concurrent treatment for AR | Duration (weeks) | Outcomes |
|---------------|---------|--------|----------|----------------|----------------|----------|-----------------|-------|------|-----------------------------|-----------------|----------|
| Meltzer 2000  | The US  | R, DB  | SAR patients aged 15–75 y | 187  | 33.6  | 44.4 | 31.1 | Montelukast 10 mg/d | Loratadine 10 mg/d | None | 2 | DNSS, NSS, CSS, DESS, RQLQ |
| Nayak 2002    | The US  | R, DB  | SAR patients aged 15–82 y | 456  | 36.6  | 36.7 | 20.9 | Montelukast 10 mg/d | Loratadine 10 mg/d | None | 2 | DNSS, NSS, CSS, DESS, RQLQ |
| Philip 2002   | The US  | R, DB  | Non-smoking SAR patients aged 15–81 y | 950  | 36.3  | 65.5 | 25.7 | Montelukast 10 mg/d | Loratadine 10 mg/d | None | 2 | DNSS, NSS, CSS, DESS, RQLQ |
| van Adelsberg 2003a | The US | R, DB  | Non-smoking SAR patients aged 15–85 y | 693  | 36.2  | 40.1 | 23.4 | Montelukast 10 mg/d | Loratadine 10 mg/d | None | 2 | DNSS, NSS, CSS, DESS, RQLQ |
| van Adelsberg 2003b | the US | R, DB  | SAR patients aged 15–82 y | 628  | 36.3  | 33.2 | 22.4 | Montelukast 10 mg/d | Loratadine 10 mg/d | None | 4 | DNSS, NSS, CSS, DESS, RQLQ |
| Lee 2004      | UK      | R, DB, CO | Adult PAR patients | 12  | 42    | 33.3 | NR  | Montelukast 10 mg/d | Fexofenadine 180 mg/d | None | 1 | DNSS |
| Di Lorenzo 2004 | Italy | R, DB  | SAR patients aged 12–50 y | 40  | 31.8  | 35  | NR  | Montelukast 10 mg/d | cetirizine 10 mg/d | Fluticasone propionate aqueous nasal spray | 6 | DNSS |
| Hseh 2004     | China   | R, DB  | Child PAR patients aged 6–12 y | 40  | 8.1   | 62.5 | NR  | Montelukast 5 mg/d | Cetirizine 10 mg/d | None | 12 | DNSS |
| Ciebiada 2006-levo | Poland | R, DB, CO | Adult PAR patients aged 18–65 y | 20  | 23.7  | 30  | 0   | Montelukast 10 mg/d | Levocetirizine 5 mg/d | None | 6 | DNSS, DESS |
| Ciebiada 2006-deslo | Poland | R, DB, CO | Adult PAR patients aged 18–65 y | 20  | 34.1  | 20  | 0   | Montelukast 10 mg/d | Desloratadine 5 mg/d | None | 6 | DNSS, DESS |
| Jiang 2006    | China   | R      | PAR patients aged 15–65y | 63  | 28.6  | 41.3 | NR  | Zafirlukast 40 mg/d | Loratadine 10 mg/d | None | 2 | DNSS |
| Philip 2007   | the US  | R, DB  | PAR patients aged 15–85y | 752  | 35.5  | 33.1 | 23.7 | Montelukast 10 mg/d | Cetirizine 10 mg/d | None | 6 | DNSS, RQLQ |
| Lu 2009-1     | the US  | R, DB  | SAR patients aged 13–85 y | 228  | 35.2  | 36.3 | 24.1 | Montelukast 10 mg/d | Loratadine 10 mg/d | None | 2 | DNSS, CSS |
| Lu 2009-2     | the US  | R, DB  | SAR patients aged 13–85 y | 267  | 30.9  | 38.9 | 70.8 | Montelukast 10 mg/d | Fexofenadine 120 mg/d | Nasal budesonide | 4 | DNSS, RQLQ |
| Liu 2016      | China   | R      | SAR patients aged 16–69 y | 64  | 37.3  | 54.2 | 0   | Montelukast 10 mg/d | Loratadine 10 mg/d | Nasal mometasone | 4 | DNSS |
| Jia 2017      | China   | R      | PAR patients aged 12–56 y | 38  | 29.7  | 54.4 | 0   | Montelukast 10 mg/d | Loratadine 10 mg/d | Nasal mometasone | 4 | DNSS |

LTRAs leukotriene receptor antagonists, SAHs selective H1 antihistamines, AR allergic rhinitis, US United States, UK United Kingdom, R randomized, DB double blinded, CO crossover, SAR seasonal allergic rhinitis, PAR perennial allergic rhinitis, NR not reported, DNSS daytime nasal symptoms score, NSS nighttime symptoms score, DESS daytime eye symptoms score, CSS composite symptoms score, RQLQ rhinoconjunctivitis quality-of-life questionnaire.
patients (MD: 0.03, 95% CI −0.04 to 0.09, \( p = 0.34 \), \( I^2 = 99\% \); Fig. 3A). Only one study involving patients with perennial AR showed that LTRAs may be superior to SAHs in terms of the RQLQ (MD: −0.09, 95% CI −0.11 to −0.07, \( p < 0.001 \); Fig. 3A).

The incidence of AEs was comparable between the groups (six RCTs [9–13, 15], OR: 0.97, 95% CI 0.75 to 1.25, \( p = 0.98 \), \( I^2 = 0\% \); Fig. 3B), which showed similar results in sensitivity analyses and subgroup analyses for seasonal or perennial AR (Fig. 3B).

**Publication bias**
The funnel plots were symmetrical, suggesting a low risk of publication bias for the outcomes of the meta-analyses (Fig. 4A–F). Egger's regression tests showed similar results for the meta-analysis of DNSS (\( p = 0.582 \)). For the other outcomes, Egger's regression tests were not performed as < 10 datasets were available.

**Discussion**
The main findings of the meta-analysis were: (1) LTRAs are inferior to SAHs for improving the daytime nasal symptoms of AR, including stuffy, runny, and itchy nose and sneezing; (2) LTRAs are superior to SAHs for improving the nighttime symptoms of AR, including nasal congestion on awakening, difficulty going to sleep, and nighttime awakenings; (3) the effects of the two medications on the composite symptoms, daytime eye symptoms, and QoL for AR patients are similar; and (4) the incidence of AEs was comparable for patients in both groups. These results suggested that although the two medications were similar in terms of the overall AR symptoms (CSS), eye symptoms (DESS), quality of life (RQLQ), and incidence of AEs, SAHs are more suited for patients with primarily daytime symptoms, while LTRAs are more suited for patients with nighttime symptoms.

A few previous meta-analyses have explored the comparative role of LTRAs and SAHs in the management of AR patients. Xu et al. evaluated nine RCTs published up to 2014 and reported that for seasonal AR patients, LTRAs were inferior to SAHs in terms of the DNSS and CSS, but were superior in terms of the NSS [29]. The authors concluded that SAHs are more appropriate for daytime nasal symptoms while LTRAs are better suited for nighttime symptoms, similar to our findings. However, the superiority of SAHs over LTRAs on CSS suggested that SAHs may be better than LTRAs for improving the overall symptoms of seasonal AR [29]. However, for the CSS outcome, the authors included a dataset with overdosed montelukast (20 mg/d) in a study

### Table 2 Details of study quality evaluation via the Cochrane's Risk of Bias Tool

| Study             | Sequence generation | Allocation concealment | Blinding of participants and personnel | Blinding of outcome assessment | Incomplete outcome data | Selective outcome reporting | Other potential threats | Total |
|-------------------|---------------------|------------------------|----------------------------------------|-------------------------------|-------------------------|---------------------------|--------------------------|-------|
| Meltzer 2000      | Low                 | Unclear                | Low                                    | Low                           | Low                     | Low                       | Unclear                  | 5     |
| Nayak 2002        | Low                 | Unclear                | Low                                    | Low                           | Low                     | Low                       | Low                      | 6     |
| Philip 2002       | Unclear             | Unclear                | Low                                    | Low                           | Low                     | Unclear                   | Low                      | 4     |
| van Adelsberg 2003a | Low               | Unclear                | Low                                    | Low                           | Low                     | Unclear                   | Low                      | 5     |
| van Adelsberg 2003b | Unclear           | Unclear                | Low                                    | Low                           | Low                     | Unclear                   | Low                      | 4     |
| Lee 2004          | Unclear             | Unclear                | Low                                    | Low                           | Low                     | Unclear                   | Low                      | 5     |
| Di Lorenzo 2004   | Unclear             | Unclear                | Low                                    | Low                           | Low                     | Low                       | Low                      | 5     |
| Hsieh 2004        | Low                 | Unclear                | Low                                    | Low                           | Low                     | Low                       | Unclear                  | 5     |
| Ciebiada 2006-levo | Unclear             | Unclear                | Low                                    | Low                           | Low                     | Unclear                   | Unclear                  | 3     |
| Ciebiada 2006-deslo | Unclear           | Unclear                | Low                                    | Low                           | Low                     | Un cler                   | Unclear                  | 3     |
| Jiang 2006        | Low                 | Unclear                | High                                   | High                          | Low                     | Low                       | Unclear                  | 3     |
| Philip 2007       | Low                 | Unclear                | Low                                    | Low                           | Low                     | Unclear                   | Low                      | 5     |
| Lu 2009-1         | Low                 | Unclear                | Low                                    | Low                           | Low                     | Low                       | Low                      | 6     |
| Lu 2009-2         | Low                 | Unclear                | Low                                    | Low                           | Low                     | Low                       | Low                      | 6     |
| Liu 2016          | Unclear             | Unclear                | High                                   | High                          | Low                     | Low                       | Unclear                  | 2     |
| Jia 2017          | Unclear             | Unclear                | High                                   | High                          | Low                     | Low                       | Low                      | 2     |
## Analysis of Data

### A. DNSS

| Study or Subgroup | LTRA | SAH | Mean Difference (IV, Random, 95% CI) | Mean Difference (IV, Random, 95% CI) |
|-------------------|------|-----|-------------------------------------|-------------------------------------|
| 1.2.1 SAR         |      |     |                                     |                                     |
| Melzter 2000      | -0.36| 0.16| 95 -0.34 0.17 92 7.5% -0.02 [-0.07, 0.00] |                                     |
| Lu 2016           | -0.54| 0.15| 32 -0.54 0.11 32 6.7% 0.00 [0.06, 0.00] |                                     |
| Lu 2009-2         | -0.35| 0.12| 103 -0.4 0.14 116 8.7% 0.01 [0.02, 0.04] |                                     |
| Nayak 2002        | -0.23| 0.12| 155 -0.26 0.14 301 8.9% 0.03 [0.01, 0.05] |                                     |
| Di Lorenzo 2004   | -0.11| 0.16| 20 -0.18 0.19 20 4.3% 0.07 [0.04, 0.11] |                                     |
| van Aelsteborg 2005b | -0.45| 0.21| 420 -0.5 0.22 170 8.2% 0.07 [0.03, 0.11] |                                     |
| van Aelsteborg 2005a | -0.38| 0.19| 522 -0.47 0.05 171 9.1% 0.09 [0.07, 0.11] |                                     |
| Philip 2002       | -0.13| 0.07| 348 -0.24 0.12 602 9.3% 0.11 [0.10, 0.12] |                                     |
| Lu 2009-1         | -0.36| 0.21| 112 -0.53 0.21 115 7.3% 0.17 [0.12, 0.22] |                                     |

Subtotal (95% CI)

| 1607 1668 70.0% | 0.06 [0.03, 0.09] |                                     |

**Heterogeneity:** Tau² = 0.00; Chisq = 95.30; df = 8 (P < 0.00001); I² = 92%

Test for overall effect: Z = 3.41 (P = 0.0006)

### B. NSS

| Study or Subgroup | LTRA | SAH | Mean Difference (IV, Random, 95% CI) | Mean Difference (IV, Random, 95% CI) |
|-------------------|------|-----|-------------------------------------|-------------------------------------|
| 1.2.2 PAR         |      |     |                                     |                                     |
| Jiang 2006        | -0.55| 0.18| 32 -0.45 0.15 31 5.6% -0.10 [-0.18, -0.02] |                                     |
| Giebala 2006-destilo | -1.03| 0.16| 10 10.99 0.13 10 3.6% -0.04 [-0.17, 0.09] |                                     |
| Lee 2004          | -0.33| 0.14| 6 -0.3 0.17 6 2.3% -0.03 [-0.21, 0.10] |                                     |
| Philip 2007       | -0.05| 0.1| 630 -0.07 0.19 123 8.4% 0.02 [-0.01, 0.03] |                                     |
| Ju 2019           | -1.96| 0.25| 19 2.01 0.19 19 3.1% -0.06 [-0.23, 0.17] |                                     |
| Giebala 2006-levy | -1.13| 0.15| 10 -1.23 0.17 10 3.2% 0.10 [0.04, 0.24] |                                     |
| Haken 2004        | -0.38| 0.21| 20 -0.56 0.18 20 3.8% 0.18 [0.06, 0.30] |                                     |

Subtotal (95% CI)

| 727 218 30.0% | 0.02 [0.05, 0.08] |                                     |

**Heterogeneity:** Tau² = 0.00; Chisq = 17.21; df = 6 (P = 0.009); I² = 65%

Test for overall effect: Z = 0.55 (P = 0.58)

### C. CSS

| Study or Subgroup | LTRA | SAH | Mean Difference (IV, Random, 95% CI) | Mean Difference (IV, Random, 95% CI) |
|-------------------|------|-----|-------------------------------------|-------------------------------------|
| 1.3.1 SAR         |      |     |                                     |                                     |
| Melzter 2000      | -0.29| 0.15| 95 -0.19 0.1 92 15.4% -0.10 [-0.14, -0.06] |                                     |
| Philip 2002       | -0.14| 0.07| 348 -0.09 0.06 602 24.6% -0.05 [-0.06, -0.04] |                                     |
| van Aelsteborg 2003b | -0.36| 0.18| 420 -0.32 0.16 170 17.8% -0.04 [-0.07, -0.01] |                                     |
| Nayak 2002        | -0.17| 0.09| 155 -0.14 0.07 301 22.5% -0.03 [-0.05, -0.01] |                                     |
| van Aelsteborg 2003a | -0.28| 0.14| 522 -0.28 0.14 171 19.8% 0.00 [-0.02, 0.02] |                                     |

Total (95% CI)

| 1540 1336 100.0% | -0.04 [-0.06, -0.02] |                                     |

**Heterogeneity:** Tau² = 0.00; Chisq = 28.49; df = 4 (P = 0.0003); I² = 85%

Test for overall effect: Z = 3.59 (P = 0.0003)

### D. DESS

| Study or Subgroup | LTRA | SAH | Mean Difference (IV, Random, 95% CI) | Mean Difference (IV, Random, 95% CI) |
|-------------------|------|-----|-------------------------------------|-------------------------------------|
| 1.6.1 SAR         |      |     |                                     |                                     |
| Melzter 2000      | -0.28| 0.14| 95 -0.25 0.13 92 15.9% -0.03 [-0.07, 0.01] |                                     |
| van Aelsteborg 2003b | -0.37| 0.19| 420 -0.39 0.18 170 10.9% 0.02 [-0.01, 0.05] |                                     |
| Nayak 2002        | -0.2| 0.1| 155 -0.23 0.12 301 18.5% 0.03 [-0.01, 0.05] |                                     |
| Philip 2002       | -0.13| 0.07| 348 -0.47 0.05 171 17.4% 0.02 [-0.02, 0.08] |                                     |
| van Aelsterb 2003a | -0.28| 0.14| 522 -0.4 0.18 171 17.4% 0.12 [0.06, 0.19] |                                     |

Subtotal (95% CI)

| 1540 1336 88.2% | 0.04 [0.01, 0.08] |                                     |

**Heterogeneity:** Tau² = 0.00; Chisq = 47.49; df = 4 (P = 0.00001); I² = 91%

Test for overall effect: Z = 1.03 (P = 0.30)

### 1.6.2 PAR

| Study or Subgroup | LTRA | SAH | Mean Difference (IV, Random, 95% CI) | Mean Difference (IV, Random, 95% CI) |
|-------------------|------|-----|-------------------------------------|-------------------------------------|
| Giebala 2006-destilo | -0.84| 0.16| 10 -0.81 0.15 10 4.9% -0.03 [-0.17, 0.11] |                                     |
| Giebala 2006-levy | -0.54| 0.14| 10 -0.66 0.1 10 6.9% 0.16 [0.05, 0.27] |                                     |

Subtotal (95% CI)

| 1560 1356 100.0% | 0.05 [0.01, 0.08] |                                     |

**Heterogeneity:** Tau² = 0.00; Chisq = 52.81; df = 6 (P = 0.00001); I² = 89%

Test for overall effect: Z = 2.61 (P = 0.009)

Test for subgroups differences: Chisq = 0.09; df = 1 (P = 0.77); I² = 0%
and another study investigating the acute effects of montelukast [35], which may have confounded the results. Our study, on the other hand, which was limited to head-to-head comparative RCTs with at least 1 week of treatments, showed similar CSS in patients treated with LTRAs and SAHs. The results suggested the two medications had similar efficacy on the overall symptoms of AR, which support their recommendation in the 2017 Japanese Guidelines [25]. Moreover, both the results of our study and Xu et al’s meta-analyses suggest that LTRAs are better suited for nighttime AR symptoms, which supports the recent recommendation in the 2018 Chinese Guidelines [26]. This is important for clinical practice since the physician’s preference for a certain medication is determined by the main symptoms of the patients. Of note, another meta-analysis published in 2016 aimed to compare the efficacy and safety of SAHs versus montelukast for AR [30]. The results of the meta-analysis

![Forest plots for the meta-analysis comparing the effects of LTRAs and SAHs on A RQLQ and B the incidence of AEs in patients with AR. LTRAs leukotriene receptor antagonists, SAHs selective H1-antihistamines, RQLQ rhinoconjunctivitis quality-of-life questionnaire, AEs adverse events.](image)
showed that montelukast was inferior to SAHs in terms
of the DNSS, but superior in terms of the NSS. However,
the authors applied a network meta-analysis design and
included studies with indirect comparisons between
montelukast and SAHs, which also confounded the
results [30]. Our study included only direct comparative
RCTs and up-to-date evidence and the results provide
further confirmation of the comparative efficacy and
safety of LTRAs and SAHs in clinical practice. During the
preparation of this manuscript, a meta-analysis regarding
the role of montelukast as treatment for AR has been
published [36]. This study contains a comparative study
between montelukast and oral antihistamine for AR.
The authors concluded that montelukast was inferior
to oral antihistamine in improving DNSS, CSS, DESS,
and RQLQ, while montelukast was superior to oral
antihistamine in improving NSS [36]. However, regarding
antihistamine medication, only studies loratadine were
included rather than studies with other SAHs. Besides,
no subgroup analysis regarding patients with seasonal
or perennial AR was performed. Our study included all available studies comparing LTRAs and SAHs in AR patients, and provided subgroup data regarding the type of AR of the included patients. Accordingly, our meta-analysis could provide a more comprehensive finding regarding the comparative efficacy of LTRAs and SAHs as treatment for AR.

For patients with AR, nighttime symptoms are bothersome, which usually leads to sleep disturbance and daytime tiredness, thereby significantly decreasing QoL in these patients [37]. In a previous study using actigraphy, the author showed that specific sleep disturbances in patients with perennial AR that may result in the increased tiredness, fatigue, and impaired QoL typically experienced in such patients [38]. These facts highlight the importance of our meta-analysis that LTRAs are better suited for nighttime AR symptoms. The potential reasons for the superiority of LTRAs over SAHs on nighttime symptoms in AR patients are unknown. Generally, nasal congestion is considered the main pathological cause of impaired sleep quality in AR patients [39], while nasal congestion may be less relevant to daytime nasal symptoms including stuffy, runny, and itchy nose and sneezing [40]. A previous study indicated that LTRAs are associated with improved nasal congestion [7], which is a late-phase manifestation of increased nasal mucosal inflammation. SAHs are associated with reduced hypersensitivity of the nose and less severe early-phase symptoms during the nasal inflammatory response, such as rhinorrhea, sneezing, and pruritus [8]. Further, LTRAs such as montelukast are usually administered before nighttime [41], which may also be responsible for their superiority in controlling nighttime symptoms. Additional studies are warranted to further explore the potential mechanisms underlying the suitability of the two medications according to the patient’s symptoms.

We performed subgroup analyses to explore the potential differences between LTRAs and SAHs in patients with seasonal or perennial AR. The results of our meta-analysis were mainly driven by studies that included patients with seasonal AR. The differences between LTRAs and SAHs became non-significant when only studies with perennial AR were considered (e.g., DNSS). Therefore, the comparative efficacy and safety of LTRAs and SAHs in patients with perennial AR remain to be clarified in large-scale RCTs. Interestingly, the only study that compared the effects of LTRAs and SAHs on RQLQ in patients with perennial AR showed a superiority of LTRAs over SAHs [19]. The reason for this finding is currently unknown. However, it can be assumed that patients with perennial AR are more likely to have nasal congestion and related sleep disturbance, which may be an important component of poor RQLQ in this population. The superiority of LTRAs over SAHs for nasal congestion and nighttime symptoms may explain the benefits of LTRAs for RQLQ in patients with perennial AR. Unfortunately, the degree of nasal congestion and changes in nighttime symptoms were not evaluated in this study [19]. More clinical studies are needed to validate this hypothesis.

Our study has several limitations. Firstly, the ages of the included patients varied. Due to the lack of study data stratified by ages, we were unable to compare the safety and efficacy of LTRAs and SAHs in pediatric and adult patients. Secondly, significant heterogeneity remained in some outcomes, which may be explained by the differences in patient characteristics, medication regimens, and follow-up durations. Thirdly, LTRAs are suggested to be effective for asthma. LTRAs are assumed to have better efficacy for patients with AR and asthma. Although some of the patients who were included in the studies had asthma, we were unable to compare the efficacy and safety of LTRAs and SAHs in these patients because stratified results were not reported. Finally, in view of the potential preference of LTRAs and SAHs for AR patients according to their symptoms, combined treatment with the two medications may achieve better symptom improvement, which should be validated in future studies.

Conclusions
The results of this meta-analysis of head-to-head RCTs showed that although both medications are safe and effective in improving the QoL. of AR patients, LTRAs are more effective in improving nighttime symptoms but less effective in improving daytime nasal symptoms compared to SAHs. These findings were mainly driven by studies that included seasonal AR patients. Further studies are needed to compare the efficacy and safety of LTRAs and SAHs in patients with perennial AR and to determine the efficacy of a combined treatment with the two medications for AR patients.

Abbreviations
AEs: Adverse events; AR: Allergic rhinitis; CIs: Confidence intervals; CSS: Composite symptoms score; DESS: Daytime eye symptoms score; DNSS: Daytime nasal symptoms score; H1R: Histamine 1 receptor; LTRAs: Leukotriene receptor antagonists; MD: Mean difference; NSS: Nighttime symptoms score; QoL: Quality of life; OR: Odds ratio; RCTs: Randomized controlled trials; RQLQ: Rhinoconjunctivitis quality-of-life questionnaire; SAHs: Selective H1-antihistamines.

Acknowledgements
We thank Medjaden Bioscience Limited for professional English-language proofreading and editing of the manuscript, assisted by MSD China.
Authors' contributions

YF and LC designed the study. YF and Y-PM performed literature search and data extraction. Y-YD and C-YQ performed statistical analyses. YF and LC interpreted the results. YF drafted the manuscript. LC revised the manuscript, and all the co-authors approved its submission. All authors read and approved the final manuscript.

Funding

The authors received no specific funding for this work.

Availability of data and materials

The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no conflict of interest.

Author details

1. Department of Otolaryngology-Head and Neck Surgery, The First Hospital, Shanxi Medical University, Taiyuan, China. 2. Shanxi Key Laboratory of Otorhinolaryngology-Head and Neck Cancer, Taiyuan, China. 3. Henan Vocational College of Applied Technology, Zhengzhou, China. 4. Department of Otorhinolaryngology & Clinical Allergy Center, The First Affiliated Hospital, Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, China. 5. International Centre for Allergy Research, Nanjing Medical University, Nanjing, China.

Received: 27 February 2021    Accepted: 14 June 2021

Published online: 29 June 2021

References

1. Meng Y, Wang C, Zhang L. Recent developments and highlights in allergic rhinitis. Allergy. 2019;74:2320–8.
2. Bayar Muluk N, Rafaeqeh SA, Cing C. Anti-IgE treatment in allergic rhinitis. Int J Pediatr Otorhinolaryngol. 2019;127:109674.
3. Schuler IV CF, Montejo JM. Allergic rhinitis in children and adolescents. Pediatr Clin N Am. 2019;66:981–93.
4. Hossenbaccus L, Linton S, Garvey S, Ellis AK. Towards definitive management of allergic rhinitis: best use of new and established therapies. Allergy Asthma Clin Immunol. 2020;16:39.
5. Cox L. Approach to patients with allergic rhinitis: testing and treatment. Med Clin N Am. 2020;104:77–94.
6. Brown T. Diagnosis and management of allergic rhinitis in children. Pediatr Ann. 2019;48:e485–8.
7. Tamada T, Ichinose M. Leukotriene receptor antagonists and antiallergy drugs. Handb Exp Pharmacol. 2017;237:153–69.
8. Kawauschi H, Yanai K, Wang DY, Itashahi K, Okubo K. Antihistamines for allergic rhinitis treatment from the viewpoint of nonsedative properties. Int J Mol Sci. 2019;20:2123.
9. Meltzer EO, Malmstrom K, Lu S, Prenner BM, Wei LX, Weinstein SF, et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. J Allergy Clin Immunol. 2020;105:197–22.
10. Naya AS,Philip G, Lu S, Malice MP, Reiss TF. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann Allergy Asthma Immunol. 2002;88:592–600.
11. Philip G, Malmstrom K, Hampel FC, Weinstein SF, LaForce CF, Ratner PH, et al. Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy. 2002;32:1020–8.
12. van Adelsberg J, Philip G, LaForce CF, Weinstein SF, Menten J, Malice MP, et al. Randomized controlled trial evaluating the clinical benefit of montelukast for treating spring seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2003;90:214–22.
13. van Adelsberg J, Philip G, Pedinoff AJ, Meltzer EO, Ratner PH, Menten J, et al. Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period. Allergy. 2003;58:1268–76.
14. Di Lorenzo G, Pacor ML, Pellettiere ME, Morici G, Di Gregoli A, Lo Bianco C, et al. Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis. Clin Exp Allergy. 2004;34:259–67.
15. Hsieh JC, Lue KH, Lai DS, Sun HL, Lin YH. A comparison of cetirizine and montelukast for treating childhood perennial allergic rhinitis. Pediatr Allergy Immunol. 2004;17:59–69.
16. Lee DK, Jackson CM, Soutar PC, Fardon TC, Lipworth BJ. Effects of single or combined histamine H1-receptor and leukotriene CysLT1-receptor antagonism on nasal adenosine monophosphate challenge in persistent allergic rhinitis. Br J Clin Pharmacol. 2004;57:714–9.
17. Ciebiada M, Gorska-Ciebiada M, Dubuske LM, Gorski P. Montelukast with desloratadine or levocetirizine for the treatment of persistent allergic rhinitis. Ann Allergy Asthma Immunol. 2006;97:664–71.
18. Jiang RS. Efficacy of a leukotriene receptor antagonist in the treatment of perennial allergic rhinitis. J Otolaryngol. 2006;35:117–21.
19. Philip G, Williams-Herman D, Patel P, Weinsein SF, Alon A, Gilles L, et al. Efficacy of montelukast for treating perennial allergic rhinitis. Allergy Proc. 2007;28:296–304.
20. Lu S, Malice MP, Dass SB, Reiss TF. Clinical studies of combination montelukast and loratadine in patients with seasonal allergic rhinitis. J Asthma. 2009;46:678–83.
21. Liu Y, Ye XJ, Zhao CL, Ji Q. The effect of combined therapy on seasonal allergic rhinitis. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2016;30:1049–52.
22. Ja KH, Chen XY, Zhang Y, Liao ZS. Effect of nasal glucocorticoid combined with loratadine or montelukast on allergic rhinitis. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2017;31:369–73.
23. Eguluz-Gracia I, Perez-Sanchez N, Bogas G, Campo P, Rondon C. How to diagnose and treat local allergic rhinitis: a challenge for clinicians. J Clin Med. 2019;8:1062.
24. Seidman MD, Gurgel RK, Lin SY, Schwartz SR, Baroody FM, Bonner JR, et al. Clinical practice guideline: allergic rhinitis executive summary. Otolaryngol Head Neck Surg. 2015;152:197–206.
25. Okubo K, Kuroko Y, Ichimura K, Enomoto T, Okamoto Y, Kawahashi H, et al. Japanese guidelines for allergic rhinitis 2017. Allergol Int. 2017;66:205–19.
26. Cheng L, Chen J, Fu Q, He S, Li H, Liu Z, et al. Chinese society of allergy guidelines for diagnosis and treatment of allergic rhinitis. Allergy Asthma Immunol Res. 2018;10:500–53.
27. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
28. Higgins J, Green S. Cochrane Handbook for systematic reviews of interventions Version 5.1.0. The Cochrane Collaboration. 2011. www.cochrane-handbook.org.
29. Xu Y, Zhang J, Wang J. The efficacy and safety of selective H1-antihistamine versus leukotriene receptor antagonist for seasonal allergic rhinitis: a meta-analysis. PLoS ONE. 2014;9:e112815.
30. Wei C. The efficacy and safety of H1-antihistamine versus Montelukast for allergic rhinitis: a systematic review and meta-analysis. Biomed Pharmacother. 2016;83:989–97.
31. Xiao J, Wu WX, Ye YY, Lin WJ, Wang L. A network meta-analysis of interventions Version 5.1.0. The Cochrane Collaboration. 2011. www.cochrane-handbook.org.
34. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.
35. Patel P, Patel D. Efficacy comparison of levocetrizine vs montelukast in ragweed sensitized patients. Ann Allergy Asthma Immunol. 2000;101:287–94.
36. Krishnamoorthy M, Mohd Noor N, Mat Lazim N, Abdullah B. Efficacy of montelukast in allergic rhinitis treatment: a systematic review and meta-analysis. Drugs. 2020;80:1831–51.
37. Romano M, James S, Farrington E, Perry R, Elliott L. The impact of perennial allergic rhinitis with/without allergic asthma on sleep, work and activity level. Allergy Asthma Clin Immunol. 2019;15:81.
38. Rimmer J, Downie S, Bartlett DJ, Gralton J, Salome C. Sleep disturbance in persistent allergic rhinitis measured using actigraphy. Ann Allergy Asthma Immunol. 2009;103:190–4.

39. Sardana N, Craig TJ. Congestion and sleep impairment in allergic rhinitis. Asian Pac J Allergy Immunol. 2011;29:297–306.
40. Thompson A, Sardana N, Craig TJ. Sleep impairment and daytime sleepiness in patients with allergic rhinitis: the role of congestion and inflammation. Ann Allergy Asthma Immunol. 2013;111:446–51.
41. Jarvis B, Markham A. Montelukast: a review of its therapeutic potential in persistent asthma. Drugs. 2000;59:891–928.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.